Regulation News
Financial regulation news from the SEC, FINRA, and government agencies. Track policy changes, enforcement actions, and compliance updates affecting markets.
GSK Nears 52-Week Peak on COPD Drug Approval and U.S. Pricing Developments
GSK shares advanced 0.6% in London trading, approaching a 52-week high following EU approval for Nucala in COPD and amid U.S. drug discount initiatives. Insider trading activity and the upcoming ex-dividend date remain in focus.
South Korean Regulators Eye Stricter Crypto Oversight After Bithumb's $40 Billion Error
South Korea's financial watchdog is pushing for tighter cryptocurrency regulations following a major incident at exchange Bithumb, which mistakenly distributed over $40 billion in Bitcoin to users. Authorities are considering enhanced inspections and addressing systemic vulnerabilities.
Gilead Hits 52-Week Peak on FDA Label Expansion for Yescarta, Earnings in Focus
Gilead Sciences reached a 52-week high after the FDA approved a label update for its Yescarta therapy, expanding use to a rare brain lymphoma. The stock's rally comes ahead of the company's quarterly earnings report.
Disney Shares Face Regulatory Scrutiny as FCC Probes ABC Talk Show
Walt Disney Co's stock will be monitored Monday after U.S. regulators launched an investigation into ABC's 'The View' regarding election airtime rules. Shares closed Friday at $108.70, up 3.6%.
Novo Nordisk Rebounds as FDA Vows Crackdown on Wegovy Copycats
Novo Nordisk B shares surged 5.29% after Hims & Hers halted its $49 compounded version of Wegovy, with the FDA pledging action against unauthorized copycats. The stock remains down roughly 20% over five sessions amid pricing uncertainty.
RTX Dividend Approved Amid Pentagon Scrutiny on Contractor Payouts
RTX declared a $0.68 quarterly dividend payable March 19, while investors monitor a pending Pentagon list that could restrict dividends and buybacks for underperforming defense contractors under a Trump executive order.
Hims Halts Compounded GLP-1 Pill as FDA Cracks Down, Molina Plunges on Profit Warning
Hims & Hers discontinues its $49 compounded semaglutide offering following FDA enforcement signals, sending shares down 16%. Molina Healthcare forecasts 2026 profit far below expectations, triggering a 28% stock drop.
Netflix Faces DOJ Antitrust Scrutiny Over Warner Bid Ahead of Key Market Data
Netflix shares edged lower after hours as the Justice Department examines potential anti-competitive conduct in its $82.7 billion Warner Bros Discovery acquisition. The streamer says it is unaware of any probe beyond standard merger review.
FDA Crackdown on Compounded Weight-Loss Drugs Boosts Eli Lilly Shares
Eli Lilly's stock rose 3.7% after the FDA warned Hims & Hers to halt sales of a non-approved compounded GLP-1 weight-loss pill, signaling a regulatory clampdown that may support pricing for branded obesity drugs.
GSK Gains EU Approval for Nucala in COPD, Stock Momentum in Focus
GSK shares rose after EU regulators approved expanded use of Nucala for chronic obstructive pulmonary disease. The stock has surged 17% this week and nearly 49% over the past year.
Huntington Bank Appoints Former BNY Risk Chief as CRO Amid Regulatory Shift
Huntington Bank has named Senthil Kumar, previously the top risk officer at BNY, as its new chief risk officer. The move follows the bank's entry into a stricter regulatory category after its merger with Cadence Bank pushed assets to $279 billion.